Citations

Showing 10 of 108152 citations.

Lactoferrin Supplementation For Taste And Smell Abnormalities Among Patients Receiving Cancer Chemotherapy
Lesser, Glenn J. , Irby, Megan B. , Taylor, Richard J. , Case, Douglas, Wang, Aili , Dietrich, Andrea, Duncan, Susan E. , Taylor, Richard, Snavely, Anna C.

Mayo Clinic

No container title available | July 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-603866/v1 Get It

Abstract Purpose: Taste and smell abnormalities (TSA) are common in patients receiving chemotherapy and may lead to altered nutritional intake, treatment withdrawal, and impaired quality of life. Lipid peroxidation in the oral cavity is one cause of TSA. Lactoferrin (LFN), an iron-binding salivary protein, reduces production of lipid oxidation byproducts and has been shown to reduce perception of unpleasant flavors. To assess the feasibility of LFN as a treatment for TSA, we conducted pilot investigations among patients with cancer who self-reported TSA following onset of chemotherapy. The primary objective was to assess change in subjective taste and smell perception from baseline to completion of 30-days of LFN supplementation.Methods: Patients were treated with 750mg LFN daily for 30 days and followed for an additional 30 days without LFN. TSA was measured via the taste and smell questionnaire (TSQ) including taste (score 0-10), smell (score 0-6), and composite scores (0-16, 0=no TSA) at baseline, day 30, and day 60.Results: 26 patients enrolled; 19 remained on study at day 30 and 17 at day 60. Baseline mean TSQ scores were 6.5 (taste), 3.1 (smell) and 9.6 (composite). By day 30, mean composite TSQ score improved by 1.7 (p=0.018); taste and smell improved by 0.6 (p=.062) and 1.1 (p=.042) respectively. From baseline to day 60, mean composite TSQ score improved by 3.8 (p<.0001); taste and smell improved by 1.9 (p=.001) and 1.8 (p=.003). Conclusions: Further evaluation of LFN is warranted to determine its value for improving self-reported TSA among patients receiving chemotherapy.
Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series
Childs, Daniel S. , Quevedo, J. Fernando , Costello, Brian A. , Pagliaro, Lance C. , Childs, Daniel S

Mayo Clinic

Anti-Cancer Drugs | July 7, 2021 | Volume: 32 | Issue: 9 | Pages: 986-990

10.1097/cad.0000000000001096 | PMID 34232950 Get It

Those with metastatic urothelial carcinoma generally respond more poorly to chemotherapy after they have progression on a checkpoint inhibitor (CPI). There is interest in combining CPIs with conventional cytotoxic chemotherapies as a strategy to exploit the efficacy and immunomodulatory effects of chemotherapy. We conducted a single institution, retrospective analysis including all patients treated between May 2018 and May 2020 with carboplatin and paclitaxel, concurrently or sequential with pembrolizumab, after having progression on a CPI alone. Clinical characteristics, response by RECIST 1.1, progression-free survival, and safety/tolerance of the treatment are reported. Median age was 80 years (64–85). Five patients (100%) had visceral metastases when starting carboplatin and paclitaxel. Chemotherapy was given with concurrent pembrolizumab (four patients) or following pembrolizumab (one patient) and continued until maximum response, significant toxicity, or progression. Two patients subsequently remained on maintenance pembrolizumab. There were four partial responses and one patient with stable disease. All patients on follow-up have progressed with median time to progression of 47 weeks (18–75). Two patients died from disease progression. This case series suggests that the combination of carboplatin, paclitaxel, and pembrolizumab leads to durable freedom from progression in some with metastatic urothelial cancer, who have progressed on a CPI alone. Larger studies of chemoimmunotherapy for metastatic urothelial carcinoma are warranted.
Surgical Reduction of Spondylolisthesis During Lumbar Fusion
Barber, Joshua A, Smith, Caleb J. , Li, Jinpu , Goldstein, Christina L, Leary, Emily , Lambrechts, Mark James , Barber, Joshua A, Beckett, Nathan , Goldstein, Christina L, Cook, James L. , Choma, Theodore J.

Mayo Clinic

Clinical Spine Surgery | July 7, 2021 | Volume: 35 | Issue: 1 | Pages: E1-E6

10.1097/bsd.0000000000001230 | PMID 34232155 Get It

Study Design: This was a retrospective cohort study. Objective: The objective of this study was to quantify the rates of complication following surgical treatment for symptomatic degenerative and isthmic spondylolisthesis and to examine the association between slip reduction and complication rates. Summary of Background Data: It is unclear if the degree of spondylolisthesis reduction during lumbar spine fusion in adults influences the rate of surgical complications. Methods: This is a retrospective cohort study of 1-level and 2-level adult fusion patients with degenerative or isthmic spondylolisthesis. The degree of reduction and complications were calculated, and complication rates between those with and without reduction were compared. Results: The surgical reduction was improved by 1 Meyerding grade in 56.5% of the 140 patients included in this analysis. Of those patients, 60% had a grade 1 spondylolisthesis. In addition, 62.5% of grade 2 slips had an improvement by 1 grade. Surgical reduction during lumbar fusion did not result in a higher rate of complications compared with in situ fusion. Conclusions: During 1-level or 2-level lumbar fusion for degenerative or isthmic spondylolisthesis, a 1-grade reduction of the slip was achieved in 56% of patients in this retrospective case series. Reduction of the spondylolisthesis was not associated with a higher rate of complication when compared with in situ fusion. Level of Evidence: Level IV.
A Systematic Review of Risk Factors Associated With Distal Junctional Failure in Adult Spinal Deformity Surgery
Wagner, Scott C. , Morrissey, Patrick B. , Kaye, I. David , Sebastian, Arjun S. , McDonnell, Jake Michael , Ahern, Daniel P. , Butler, Joseph S.

Mayo Clinic

Clinical Spine Surgery | July 7, 2021 | Volume: 34 | Issue: 9 | Pages: 347-354

10.1097/bsd.0000000000001224 | PMID 34232153 Get It

Background: The surgical management of adult spinal deformity (ASD) is a major surgical undertaking associated with considerable perioperative risk and a substantial complication profile. Although the natural history and risk factors associated with proximal junctional kyphosis (PJK) and proximal junctional failure are widely reported, distal junctional failure (DJF) is less well understood. Study Design: A systematic review was carried out. Objectives: The primary objective is to identify the risk factors associated with DJF. The secondary objective is to delineate the incidence rate and causative factors associated with DJF. Methods: A systematic review of articles in Medline/PubMed and The Cochrane Library databases was performed according to preferred reporting items for systematic reviews and meta-analyses guidelines. Data was collated to determine the prevalence of DJF and overall revision rates, and identify potential risk factors for development of DJF. Results: Twelve studies were included for systematic review. There were 81/2261 (3.6%) cases of DJF. Overall, DJF represented 27.3% of all revision surgeries. Anterior-posterior surgery had a reduced incidence of postoperative DJF [5.0% vs. 8.7%; P=0.08; relative risk (RR)=1.73], as did patients below 60 years of age at the time of surgery (2.9% vs. 3.9%; P=0.09; RR=1.34). There was a higher incidence of DJF among those patients who received interbody fusion (9.9% vs. 5.1%; P=0.06; RR=1.93) compared with those who did not. However, none of these findings reached statistical significance. There were significantly more rates of DJF for fusions ending on L5 compared with constructs fused to the sacrum (11.7% vs. 3.6%; P=0.02; RR=3.28). Conclusions: Cohorts 60 years and above of age at the time of surgery and patients managed with posterior-only fusion or interbody fusion have increased incidences of DJF. Fusion to L5 instead of the sacrum significantly influences DJF rates. However, the quality of available evidence is low and further high-quality studies are required to more robustly analyze the clinical, radiographic, and surgical risk factors associated with the development of DJF after ASD surgery.
Outpatient healthcare utilization among incident cases of systemic sclerosis: results from a population-based US cohort (1988–2016)
Coffey, CM, Sandhu, AS, Crowson, C. S., Asante, Dwamena, Matteson, E. L., Osborn, T. , Sandhu, AS, Warrington, Kenneth J. , Makol, Ashima

Mayo Clinic

Scandinavian Journal of Rheumatology | July 7, 2021 | Volume: 51 | Issue: 4 | Pages: 323-328

10.1080/03009742.2021.1932581 | PMID 34232106 Get It

The impact of patient and partner personality traits on learning success for a cognitive rehabilitation intervention for patients with MCI
Khayoun, Renata, Devick, Katrina L. , Chandler, Melanie , Shandera‐Ochsner, Anne L., Wit, Liselotte De , Cuc, Andrea , Locke, Dona E.C. , Chandler, Melanie J, De Wit, Liselotte , Locke, Dona E C , Smith, Glenn E.

Mayo Clinic

Neuropsychological Rehabilitation | July 7, 2021 | Volume: 32 | Issue: 10 | Pages: 2483-2495

10.1080/09602011.2021.1948872 | PMID 34232113 Get It

The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma
Prodduturvar, Pranitha, Mneimneh, Wadad , Zotto, Valeria Dal, Akbar, Shalla, Grimm, Leander , Rider, Paul , Alkharabsheh, Omar , Patel, Girijesh Kumar , Fabregas, Jesus C. , Singh, Ajay P. , Khushman, Moh'd M. , Hunter, John

Mayo Clinic

Oncotarget | July 7, 2021 | Volume: 12 | Issue: 15 | Pages: 1490-1498

10.18632/oncotarget.28025 | PMID 34316329 Get It

An Investigation Into Miniaturised Closed-Loop DBS Devices
Corva, Dean M. , Adams, Scott , Bennet, Kevin E. , Berk, Michael , Kouzani, Abbas Z. , Kouzani, Abbas Z , Berk, Michael , Hashemi, Parastoo

Mayo Clinic

IEEE Transactions on Medical Robotics and Bionics | July 7, 2021 | Volume: 3 | Issue: 3 | Pages: 671-680

10.1109/tmrb.2021.3095361 Get It

Classification of Uremic Toxins and Their Role in Kidney Failure
Rosner, Mitchell H. , Reis, Thiago , Vanholder, Raymond , Hutchison, Colin A., Cozzolino, Mario , Juillard, Laurent, Kashani, Kianoush , Kaushik, Manish , Kawanishi, Hideki , Massy, Ziad A. , Sirich, Tammy L. , Zuo, Li , Vanholder, Raymond , Cozzolino, Mario , Kashani, Kianoush B , Ronco, Claudio , Husain‐Syed, Faeq , Stenvinkel, Peter , Blankestijn, Peter J. , Ronco, Claudio

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 7, 2021 | Volume: 16 | Issue: 12 | Pages: 1918-1928

10.2215/cjn.02660221 | PMID 34233920 Get It

Advances in our understanding of uremic retention solutes, and improvements in hemodialysis membranes and other techniques designed to remove uremic retention solutes, offer opportunities to readdress the definition and classification of uremic toxins. A consensus conference was held to develop recommendations for an updated definition and classification scheme on the basis of a holistic approach that incorporates physicochemical characteristics and dialytic removal patterns of uremic retention solutes and their linkage to clinical symptoms and outcomes. The major focus is on the removal of uremic retention solutes by hemodialysis. The identification of representative biomarkers for different classes of uremic retention solutes and their correlation to clinical symptoms and outcomes may facilitate personalized and targeted dialysis prescriptions to improve quality of life, morbidity, and mortality. Recommendations for areas of future research were also formulated, aimed at improving understanding of uremic solutes and improving outcomes in patients with CKD.
Rate of Remission Is the Most Important Determinant for Treatment Decision-Making in Graves’ Disease
Kawkgi, Omar El , Brito, Juan P.

Mayo Clinic

Clinical Thyroidology | July 7, 2021 | Volume: 33 | Issue: 7 | Pages: 316-318

10.1089/ct.2021;33.316-318 Get It